NCI-CCC Tumor Board Question
These are questions being discussed by academics at NCI-Cancer Centers
Questions discussed in this category
Total neoadjuvant therapy (TNT) included FOLFOX x 4 months and concurrent chemo-RT
If so, how many cycles would you give? Both the MAGIC and FLOT trials showed difficulty with administering adjuvant chemotherapy.
At initial diagnosis she had T1cN0 disease treated with lumpectomy and SLNB followed by 12 weeks of paclitaxel with 1 year of trastuzumab.
Would you use it for initial staging or at time of biochemical recurrence?
What type of adjuvant chemotherapy would you offer?
Would clinically positive lymph nodes or residual disease at time of surgery change your decision...
Would you consider definitive local therapy (surgery, radiation?) if she achieved a good response to initial systemic therapy?
In light of CheckMate 816 and IMpower010 and FDA approval for neoadjuvant chemo-nivolumab and adjuvant chemo-atezolizumab, how do you decide which sys...
Young patient, germline BRCA carrier with cT1cN0 to ypT2N0 disease after docetaxel/ cyclophosphamide x 4.
NGS without any actionable mutations and PD-L1 TPS 15%.
Would you offer chemotherapy, radiation, or immunotherapy and, if so, in what order?
Patient is young. Bilirubin normalizes when tucatinib is held, but again increases to grade 2 when it is restarted. Evaluation for hemolysis was negat...
Does a progressing kappa/lambda ratio > 100 at any point in time warrant treatment, or does one wait to treat patients in the setting of a slowly i...
Would you give R-CHOP without knowing if there was use of prior anthracycline?
Patient has been on pembrolizumab and had two symptomatic soft tissue mass treated with radiation.
Would you consider re-challenging with a different TKI?
Do you routinely offer post-operative adjuvant radiation in addition to chemotherapy?
Are the results of the recently published negative phase ...
Previously untreated
Which agents would you select and for how long would you treat them?
Patient is young and reoccurrence is one year after initial diagnosis of T1cN0 ER/PR positive, HER2-negative breast cancer treated with mastectomy, bu...
For pts w/ eGFR between 30-60
Frailty Index per Palumbo et al. PMID 25628469Is it practical to apply in clinics? Have you made decision changes based on it?
Patient underwent mastectomy for DCIS in the setting of previous lumpectomy and adjuvant radiation for the invasive breast cancer.
(assuming they meet MonarchE criteria)
For example, if the patient is in year 2, 3, 4, or 5 of adjuvant endocrine therapy versus 9 months out, would ...
Venetoclax has demonstrated efficacy in patients harboring t(11;14) mutations but is not FDA approved for MM. Can you expand on what situations you ma...
Does the 2020 approval of Nivolumab and Ipilimumab for mNSCLC with PDL1 >1% impact your decision?
Patient is ypT2N1
Patient has already received neo/adjuvant treatment with AC, paclitaxel, capecitabine, docetaxel, and carboplatin.
Would you consider neoadjuvant or adjuvant treatment and if so, which therapies? Patient initially had pT2N0 disease and recurrent disease is also ER+...
Patient previously received neoadjuvant ddAC-T with residual disease at surgery, followed by adjuvant capecitabine which was completed 2 months prior ...
Pathology details: 75% high grade large cell neuroendocrine tumor of the cecum (20-30 mitoses per 10 hpf, Ki67 75%) and 25% adenocarcinoma. Patient ha...
Patient is pre-menopausal and has cT3cN1, grade 2, ER positive, Her 2 negative IDC. Metastatic disease to axillary LNs was biopsy-proven. Patient was ...
For example: shorten IMiD duration each cycle, add scheduled G-CSF, add antibacterial prophylaxis, etc.
How do you decide how long to continue?
NGS of TURBT specimen had high TMB (18 Muts/Mb).
Do you observe, offer adjuvant pembrolizumab, or give a first-line metastatic regimen (IO/IO or IO/TKI)? Does your recommendation vary based on risk c...
High-risk criteria meaning >4 positive nodes and Ki67 >20%
CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?
Is a repeatedly abnormal serum immunofixation all it takes for MGUS?
PSA rose from 25 to 30 ng/mL over 6 months on darolutamide for M0 CRPC, prompting scans which showed oligometastatic disease to bone, not amenable to ...
Based on CheckMate 577?Is DFS endpoint sufficient to establish SOC or is OS benefit needed?
Would you continue with daratumumab maintenance per ANDROMEDA or switch regimen?
Would a PET avid pelvic lymph node without distant metastatic disease change your management?
Ki67 = 90% with multiple small nodes on PET scan and normal CBC
This situation can feel uncomfortable. Would this feel safer if patient is s/p mastectomy and had TNBC?
Or what is your preferred regimen for stage IV ccRCC following progression on IO/IO?
If any clinical benefit (ie. CR, PR or SD) would you consider switch maintenance avelumab, surveillance until progression, or an alternate regimen?
With the recent announcement that the phase 3 MonarchE trial met its primary endpoint.
Molecular profiling revealed no targetable alterations, however tumor mutational burden was >10 mut/Mb.
Patient in mid-30s with no major medical history presented with isolated left neck swelling. Incisional biopsy w/ HTLV1/2 associated ATLL, Ki67 of >...
Largest invasive focus is 0.4mm
What about multiple anaplastic plasmacytoma without bone marrow involvement?
Patient has progression of liver metastases while on pembrolzumab/axitinib. ECOG PS 1 and limited comorbidities.
CNS recurrence occurred within two years of prior neoadjuvant therapy
GS 4+4. PSA low (1-2). CT and bone scan negative for lymphadenopathy or metastatic disease. Prostate MRI pending.
How much weight do you give to a hgb/hct threshold versus symptoms?
Would you use MRD status to guide your decision making?
If so, venetoclax/dexamethasone by itself or do you include a PI?
Colleagues in surgery have raised concerns about post radiation effects in the pelvis with the ordering of short course RT->chemo ->surgery.
Is there any role for denosumab? How do you counsel patients regarding the benefit of bisphosphonates on breast cancer outcomes?
ER <1%; PR 45%, Her2 negative by IHC and FISH. Grade 3, Ki67: 80%.
Patient was on tamoxifen when progression occurred; unable to tolerate adjuvant AI.
How would this affect adjuvant radiation plan in breast conservation therapy patients and mastectomy patients?
Does patient age effect your approach?
Would you consider RPLND for any patients in light of the phase II SEMS trial presented at the 2021 ASCO GU Ca...
Do you have a specific age cutoff?
Patient with T2N1 disease and isolated liver metastases. Axilla and liver completely responded to chemo + IO, but limited residual breast enhancement ...
Do prior treatments for mHSPC change your thinking on whether or not to use sipuleucel-T?
Patient has not had any prior systemic treatment and is cisplatin-eligible.
What factors make you more likely to offer or omit chemotherapy?
Ampullary carcinoma is not in the NCCN guidelines. Please address not only the role for therapy but the optimal regimen (i.e. Gem based, vs mFOLFIRINO...
History of CDH1 mutation and prophylactic gastrectomy in 2017 - no other primary site found beyond vagina at diagnosis.
Vaginal tumor completely resp...
Would you consider afatinib? Afatinib has shown some activity in NRG1 fusion + patients but amplifications is unclear.
MiT subfamily translocations = TFE3, TFEB, TFC, or MiTF
Gleason 4+3=7 and PSA 4
We usually recommend copper IUDs, but that's not feasible in all women.
<40y/o female w/ initial biopsy showing G3 IDC with 80% ER+, 90% PR+, and HER2 positive (IHC 2+; 1.6 HER2/CEP17 ratio and 6.3 HER2 copies/nucleus.)...
Would you plan straight pediatric dosing using 2500 Units/m2 or a cap of 3750 Units as used in some adult ALL regimens due to excess liver/pancreas to...
Healthy 67 y/o woman, 1.5cm tumor, grade 3
In this case, nivo/ipi discontinued for immune-related arthralgias requiring steroids and an anti-TNFa agent, now off all immunosuppression.
Patient was given ddAC + T
What clinicopathological features would need to be present for you to recommend adjuvant chemotherapy? Would you treat pT3 disease? Any specific histo...
Does post docetaxel PSA influence your decision?
Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...
What line would you give pembrolizumab?
Would you offer this patient chemotherapy? What are your thoughts about OFS plus AI and avoiding chemotherapy?
Initial diagnosis was 15+ years ago
Would you choose to incorporate HER2-targeting agents, chemotherapy, endocrine therapy, or a mix of these?
58 yo, grade 1 endometrioid endometrial cancer. TLH, BSO, sentinel nodes. Stage IA, focal LVSI, 20% myometrial invasion, negative sentinel nodes, posi...
Would you change to a different CDK4/6 inhibitor or avoid the entire class of drugs?
Ex. TP53, BRCA, T790M, or another? As of now, T790M mutation is one of the few de novo mutations found in treatment naïve patients th...
I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...
At what frequency and for how long should echos be monitored?
Are there particular patient characteristics (e.g. age, ER%, Ki67, grade) that make you more likely to choose neoadjuvant endocrine therapy?
Would a pCR to neoadjuvant chemotherapy change your management? (ER <5%, PR <5%)
Do features such as nodal involvement, Ki-67, degree of ER positivity, etc. change your management? Would you use any gene expression assays to help y...
Are there any data to support a specific TKI therapy for non-T790M exon 20 mutations/insertions?
Would you prefer TCHP over TCH? Would you consider adding an anthracycline?
How would you approach additional systemic therapy? Would the clinical stage of the cancer affect your management?
Specifically, for cT2N0M0 small cell bladder cancer without response to neoadjuvant cisplatin and etoposide on imaging, would you proceed with cystect...
Is adjuvant radiation and/or adjuvant chemotherapy indicated?
Would you try atezolizumab/bevacizumab or switch to a TKI?
Would you consider an Oncotype or Mammaprint? Would your management change if the patient had 1-3 positive LNs on SLNBx (as opposed to ALND)?
What neoadjuvant or adjuvant therapy would you give?
Would you send Oncotype during chemotherapy if not sent already? Would you stop adjuvant chemotherapy if a prior Oncotype was 25 or less?
What is your specific therapy choice and duration?
Would you send an Oncotype RS to determine the role of adjuvant chemotherapy and/or endocrine therapy?
Would you consider gene profiling to determine need for chemotherapy?
In a patient who is not a surgical candidate, do you offer concurrent carbo/taxol rather than 5FU/oxaliplatin?
How would you balance the competing risks of these two diagnoses in her treatment?
Patient had a clinical T2N0 cancer at diagnosis, completed 6 cycles TCHP, and had 0.2mm residual disease with 80% cellularity, negative sentinel node.
How do clinical risk and Mammaprint/Oncotype scores affect your decision?
For example, will you recommend a certain vaccination timing in relationship to their treatment? Any concerns for reduced immune response or risks of ...
Patient underwent an axillary dissection with ITCs in 1/23 nodes.
Ex: TKI alone, TKI + checkpoint inhibitor, checkpoint inhibitor alone, TKI + mTOR inhibitor. Please specify drug regimen, if applicable.
Pathology is not carcinoid or small cell.
Would it change your decision if they had progressed on a first-line trial with cisplatin followed by pembrolizumab plus enfortumab vedotin maintenanc...
What factors would determine your consideration of this as a recurrence versus a new primary and how would that influence your decision?
Does tumor size impact your recommendation? High grade? Young patient age?
Does the advent of more effective therapies like peptide receptor radioligand therapy (PRRT) and capecitabine and temozolomide (CAPTEM) dampen enthusi...
Does lymph node positivity change your management?
Would you consider ALND and /or XRT to axilla?
Patient case is triple positive inflammatory breast cancer
Of note, the patient received cytotoxic plus HER2 directed adjuvant therapy but declined endocrine therapy.
Would you use FOLFIRINOX as in Prodige 23 or FOLFOX as in RAPIDO?
Chemoradiation completed 1.5 years prior
The patient went straight to gastrectomy for clinical T1 gastric adenocarcinoma, but post-op was up-graded to T4 disease.
Both ARTIST and Inte...
Pre-menopausal women make progesterone and their menses are typically lighter on tamoxifen because it's a mild endometrial ER stimulant blocking their...
Patient completed neoadjuvant therapy with TCH 2 years prior, and has no evidence of disease outside the CNS on PET/CT.
Would you test initial core biopsy (prior to neoadjuvant anastrozole) or surgical specimen? Any preference for Oncotype vs. Mammaprint?
SRS done to the single brain met, PD-L1 5%, BRAF G469A mutation
Would your answer change if the new lesion is ALH/ADH?
The patient remains without evidence of systemic disease outside of the CNS on serial imaging. Would you continue treating with SRS as lesions appear,...
Would you recommend additional cytotoxic chemotherapy and/or switch her anti-Her therapy to T-DM1?
For a patient with high risk disease and a severe enough reaction that additional taxane-based therapy is contraindicated, do you consider alternate c...
Is there an advantage to early diagnosis and intervention versus observation until the nodules are amenable to percutaneous biopsy?
She had had 4 prior biopsies. Would the fact that she received 2 months of neoadjuvant tamoxifen due to COVID change your approach?
Patient completed adjuvant AC-T 8 months prior to recurrence. BRCA negative, foundation medicine NGS pending.
PD-L1 is low and she has residual neuropathy from neoadjuvant paclitaxel.
What are there most evidence-based options?
Out of curiosity, I did tumor testing, and she does not have an activating ESR1 mutation.
Is there any evidence for sacituzumab govitecan (IMMU-132) in this situation with progressive systemic disease after prior anthracycline and taxane?
If yes, would you offer tamoxifen or ovarian suppression plus AI?
This patient underwent mastectomy and ALND (10/28 positive lymph nodes). Immediately following axillary LN dissection (and prior to radiation) imaging...
Data from the SOFT/TEXT trials showed clinical benefit in ovarian suppression + aromatase inhibition for high risk, premenopausal ...
Would you treated with local therapies (RFA or SRS) and continue pembrolizumab or would you move to second line treatment?
Would you consider genomic assays before neoadjuvant chemotherapy? How would you modify your treatment given the COVID-19 pandemic?
Would you continue to trend ctDNA to detect early recurrence?
Upfront surgery vs neoadjuvant therapy? And if neoadjuvant therapy, which regimen?
Patient has a good PS.
What are the risks of infection with COVID-19 if using immunotherapy?
Would your choice vary based on the patient's gender?
Should staging and treatment decisions be made based on imaging alone?
Personally, my practice is to guide patients directly to surgery or to do neoadjuvant chemotherapy rather than to do neoadjuvant endocrine therapy, bu...
For example, if you had a triple positive breast cancer found on breast biopsy and repeat ER/PR/HER2 testing at the time of surgical resection showed ...
If so, how long is too long to wait?
This patient is interested in conceiving and therefore would like to wait to start the tamoxifen.
Do you ever consider stopping if stable disease and good tolerance?
For example, if a patient had testosterone pellets injected, perhaps making endocrine therapy less efficacious, would that sway you to use chemo?
Being that this is a favorable histology would you use Oncotype Dx to help decide on neoadjuvant chemotherapy? Would you recommend neoadjuvant endocri...
Most trials establishing CRT as standard of care for IIIB NSCLC excluded patients with separate ipsilateral lung nodules given that they were categori...
Would you treat this differently than someone who only presents with axillary nodal disease?
In your experience, what approach has been successful to bridge to surgery?
How, if any, do you utilize genomic testing to guide systemic therapy?
Especially if you don't have trials available at the moment.
Would you try off-label erdafitinib (given recent data on bladder cancer) or 2nd line ge...
Additionally, would the finding of any mutations, such as ESR1, change your recommendation?
For example, is this still your approach in women with small tumors or node negative disease?
If so, for what platelet count threshold and do you have a preference as to which agent?
PET-CT and Brain MRI are negative for other evidence of disease.
Would nivo + Ipi be appropriate in this situation, especially if high TMB?
Especially in light of the new Guardant data presented at AACR 2019
In the absence of a frontline clinical trial, would you treat with carboplatin+pemetrexed+pembrolizumab or consider IMPOWER 150 or other?
Knowing that benefit of contralateral mastectomy is lower in older women who has already manifested BRCA related cancer and 10-20 % mastectomy related...
What would be the next line of treatment, PRRT, capecitabine and temozolomide or other?
In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alte...
The NCCN guidelines regard MET exon 14 skip mutation as an emerging biomarker but no formal recommendation to start crizotinib. If high P...
Is there any advantage of one regimen over the others?
Is this new SSO choosing widely guideline being widely adopted and are there any concerns regarding this for clinical practice?
If finished adjuvantly, what would you do -- continue TC or change chemotherapy?
If yes, would you still recommend dual HER2 directed therapy?
After the TRYPHAENA trial, neoadjuvant therapy with dual HER2 directed therapy has beco...
Given that DBA is associated with increased incidence of MDS, AML and other solid tumors, would this modify your treatment recommendations?
For early stage disease in a single breast, would you consider neoadjuvant chemotherapy or upfront surgical staging followed by adjuvant therapy? What...
Given the potential high risk of developing pneumonitis with TKI post checkpoint inhibitor, do you avoid TKIs and try a different regimen (ex carbo/pa...
If so, what is your approach to sequencing and timing of targeted therapy and local therapy?
RP node with treatment related changes and surgical specimen from TAH/BSO no other foci of malignancy found.
I have seen anywhere from 4-6 months utilized. Is there any data to guide your strategy?
Does your approach differ by EBV status?
Provided the sternal lesion was low volume and treated with curative intent and patient has been on tamoxifen for < 5 years, would you switch to AI...
If so, after how many cycles of chemotherapy would you switch?
Does hormone receptor status impact your decision?
Following SRS to the brain lesions, is it safe to closely follow the patient for recurrence?
Tamoxifen prophylaxis has not been studied in women <35 years old, but it would be reasonable to assume they would benefit.
In a patient with who had undergone neoadjuvant TCH-P, lumpectomy, and RT and is currently on AI, pertuzumab, and trastuzumab, how do you think about ...
If so do you favor repeat tumor biopsy or cfDNA?
Would you forego anthracycline?
Do you offer consolidation chemotherapy prior to durvalumab in locally advanced, unresectable NSCLC?
In clinical practice, consolidation chemotherapy is sometimes used, though this was not implemented in the PACIFIC trial.
https://www.ncbi.nlm.nih.go...
Do you see a role for adjuvant radiation therapy?
Patient has hot flashes.
http://abstracts.asco.org/239/AbstView_239_262655.html
If so, would you combine them vs monotherapy? Patient ECOG is 1
Why do the NCCN guidelines suggest using neoadjuvant therapy only for patients with T2 or greater tumors?
If so, would you treat as node + BC with anthracycline and taxane regimen or non-anthracycline regimen (i.e docetaxel and cyc...
greatest measuring 1.0cm.
Or would you proceed with standard-of-care adjuvant approach for high risk patients?
I.e. according to Mammaprint test?
Retrospective data suggest clinically significant disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung canc...
The EGFR subgroup appeared not have benefited as much as other patients in the publication. However, recently it was reported that the PACIFIC study m...
Patient did not receive neoadjuvant therapy.
If it is still within the 12 month period and no disease recurrence?
Is there a point at which there may be no benefit? More than 3 months from breast surgery? 6 months? 1 year?
Would you maintain dose density of chemotherapy and use peg-filgrastim prior to delivery of the baby? Would you defer taxane and anti-HER2 therapy unt...
If so, what would be the regimen that you would consider and what factors would sway you for or against chemotherapy for such patients?
Would you give adjuvant chemotherapy or start osimertinib?
The CALOR trial included patients that could receive HER2-targeted therapy.
Some retrospective data reports that STK11 (AKA LKB1) makes NSCLC resistant to immunotherapy.
No other site of metastatic disease. It is unclear if this situation should be managed as two separate primaries or metastatic disease.
Would you consider neo-adjuvant chemotherapy or treat with endocrine therapy?
Do your recommendations differ if patients are pre or postmenopausal given the data?
Have the results from IMpassion130 changed the standard of care?
Does the answer vary based on whether it is neo/adjuvant or metastatic setting?
How applicable is the SOFT/TEXT data in this setting ?
Would you consider radiation and/or chemotherapy?
Initial pathology additionally yields low Ki-67 and is HER2 negative.
What if the patient has thymoma-associated myasthenia gravis?
Carbo/pemetrexed/pembrolizumab, carbo/pemtrexed without immunotherapy or second line immunotherapy (Nivo, Pem or atezolizumab)?
All tumors in this case were <2cm in size.
(HER2/CEP17 ratio <2.0, copy number >4.0 and <6.0 signals/cell)
There is no evidence of disease outside the lung on PET, and the patient is completely asymptomatic with negative EGFR, ALK, ROS1, and BRAF and a PD-L...
PD-L1 < 50% and no targetable mutations. Would you use carbo/pemetrexed/pembrolizumab or Nivolumab or pembrolizumab?
How does the timing of recurrence play into your decision?
Lung primary is inaccessible for biopsy and metastatic sites are only 2 small bone lesions. In a non-smoker, a driver mutation is suspected but would ...
Would you offer adjuvant therapy post resection?
In the setting of the recent TailorRx data, would these patients be considered more high risk?
Pt is healthy and tolerating Tamoxifen well.
In a patient treated over 10 years ago with mastectomy and chemo now with recurrence in the ipislateral axilla, would you offer additional with chemot...
Can these patients be re-challenged with Herceptin?
Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however ...
Would you do this for ER+ patients?
According to the PERSEPHONE trial presented on ASCO 2018, in HER2+, non-metastatic breast cancer, 6 months Hercep...
If there is no response to neoadjuvant AC -->T, would you offer additional adjuvant chemotherapy?
Patients are understandably concerned about the risks and benefits of radiation to an oozing, bleeding, ulcerated breast.
High enough risk to justify anthracycline+taxane chemotherapy followed by ovarian suppression + aromatase inhibition.
If so, how frequently?
Pt clinically has inflammatory breast cancer making mastectomy a poor option.
First episode was 10 years ago and patient did not receive XRT. Would you give XRT now?
Do you offer additional adjuvant chemotherapy, proceed to adjuvant endocrine therapy, or search for a suitable clinical trial?
No prior chemotherapy.
Patient does not qualify for breast cancer screening by annual MRI per criteria (IBIS lifetime risk<20%, no known genetic predisposition,...
When would you favor delivering local therapy (e.g. SBRT) prior to systemic therapy?
Would you treat this as a locally advanced breast cancer and offer surgery, radiation, and systemic therapy? Does your management change depending on ...
These patients have been largely excluded from these trials. What if the infection is well controlled?
An article (BRCA mutation and outcome in BC. Ellen Copson, et al. Lancet Oncol. 2018) showed G3, BRCA+ breast cancer had poorer prognos...
If so, when? Are there certain ERBB2 mutations that would predict response to trastuzumab and/or neratinib?
Following the dosage guidelines based on absolute neutrophil count may cause the patient to end up receiving lower doses.
This is in regards to the risk of secondary cancers after radiation therapy or cytotoxic chemotherapy (such as anthracyclines) in an immunosuppre...
What do you do with low grade (grade 1/3) tumors? In other words, does high grade pathology over rules?
Would you use a regimen with lower incidence of neurotoxicity such as CMF or a taxane-based regimen with a low threshold to dose-reduce?
Some patients request chemotherapy scheduling adjustments to avoid feeling ill on major holidays. Delaying chemotherapy by a few days isn't of particu...
Example case: Patient given neoadjuvant docetaxel + cyclophophamide achieves a partial response after 3 cycles of Taxotere + cyclophosphamide but is u...
How often will you monitor it? In the setting that patient is morbidly obese, does your strategy change?
Tamoxifen prophylaxis is FDA-approved, but would you extrapolate from adjuvant/metatastic data for hormone receptor positive breast cancer in post-men...
In the absence of data demonstrating a clinical benefit for one strategy versus the other, what do you do in practice?
There is limited data that suggests steroidal AI exemestane could be of some benefit after nonsteroidal AI failure (Lonning PE et al. J Clin Oncol 200...
For example, would you order a PET/CT to evaluate for lymphatic or distant metastatic disease?
Does your institution do this routinely?
I.e. either for treatment of high-risk disease or intolerance/contraindication to tamoxifen. Will you continue it for the full 5 year course?
Do you prefer doing this through a "neoadjuvant" approach vs. post-operatively?
CALOR trial
How does the modest results of the APHINITY trial impact your practice?
In a patient with isolated leptomeningeal disease (no systemic disease), would you still recommend systemic therapy?
Do you reserve this approach for only women with triple negative breast cancer or all-comers?
Is this in addition to or mutually exclusive from oncotype/mammaprint?
Patient has hormone-refracatory disease, had high visceral burden (pulmonary mets, bone, lymph). Progressed on taxane, xeloda, gemcitabine. Now ...
What would you choose if there is no response to neoadjuvant AC-T? Taxol, THP, TCHP?
(For instance, TCX4 instead of AC->T for smaller tumors?)Does this affect your decision about treating with neoadjuvant versus adjuvant chemotherap...
How would the new data presented at ASCO GI 2021 from from Alliance A021501 influence your answer?
At what point do you send these test, and in what instances do the results influence your treatment recommendations?
Would you offer adjuvant TKI following ADAURA data? Or proceed with durvalumab based on PACIFIC data?
What is the best management for a local recurrence for a stage I NSCLC treated previously with SBRT?
Should fractionated EBRT be administered or can repeat SBRT be used?
Papers discussed in this category
International journal of radiation oncology, biology, physics, 2013-03-15
International journal of radiation oncology, biology, physics, 2011-05-01
International journal of radiation oncology, biology, physics, 2011-11-01
The New England journal of medicine, 2015-03-05
N. Engl. J. Med., 2015-01-29
Lancet, 2007-05-19
The Lancet. Oncology, 2016-12
Nat. Med.,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-01
Clinical breast cancer, 2006-12
Lancet (London, England), 2009-12-19
The Lancet. Oncology, 2014-06
The New England journal of medicine, 2012-11-08
J. Clin. Oncol.,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-03-15
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10
J. Clin. Oncol., 2019 Oct 16
N. Engl. J. Med., 2017-07-13
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015-04
Am J Case Rep, 2017-02-28
The New England journal of medicine, 2016-08-25
N. Engl. J. Med.,
Lancet, 2017-09-09
Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09
Oncologist, 2007-09-01
Journal of the National Cancer Institute, 2006-12-20
Medicine and science in sports and exercise, 2010-07
J Clin Oncol, 2016 Feb 20
Curr Breast Cancer Rep, 2016-01-01
Crit Rev Food Sci Nutr, 2018 Apr 19
JAMA, 2018-02-20
JAMA Oncol,
The New England journal of medicine, 2012-08-02
Lancet (London, England), 2016-12-17
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01
Breast cancer research and treatment, 2012-11
N Engl J Med,
British journal of clinical pharmacology, 2016-06
The New England journal of medicine, 2014-07-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-01
Fertility and sterility, 2016-03
Breast Cancer, 2017-09-01
Journal of the National Cancer Institute, 2010-07-07
J Natl Cancer Inst, 2006 Jul 5
J. Natl. Cancer Inst., 2010-07-07
J. Clin. Oncol., 2003-10-01
Breast Cancer Res. Treat., 2005-01-01
Breast, 2016-12-01
Zhonghua Zhong Liu Za Zhi, 2016-07-01
Breast, 2016-08-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10
Cancer, 2010-11-15
The breast journal, 2017-11
The New England journal of medicine, 2011-06-23
Lancet (London, England), 2016-02-27
Cancer investigation, 2011-11
Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-12-01
Cancer Treat. Rev., 2011-10-01
Annals of oncology : official journal of the European Society for Medical Oncology, 2015-07
Ann. Oncol., 2013-12-01
Nat Rev Clin Oncol, 2016-08-01
The Lancet. Oncology, 2018-02
Ann. Oncol.,
Clin. Cancer Res., 2018 Mar 26
Science translational medicine, 2013-12-18
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-02
Ann. Oncol.,
Breast Cancer, 2012 Apr 25
Annals of surgical oncology, 2018-10
Lancet Oncol., 2015 Sep 09
Cancer, 2004-10-15
The New England journal of medicine, 2018-12-13
Lancet Oncol., 2016 Jun 23
BMJ, 2016 Sep 30
The New England journal of medicine, 2018-07-12
Journal of the National Cancer Institute, 2017-02
N Engl J Med, 2015 Jan 8
Annals of internal medicine, 2018-01-16
N Engl J Med, 2017 Nov 16
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-12-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10
The Lancet. Oncology, 2012-07
Annu. Rev. Med., 2015 Aug 28
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-06-20
Lancet,
Lancet Oncol, 2019 Feb 19
Lancet Oncol, 2019 Dec 02
Lancet Oncol, 2017 Oct 13
JNCI Cancer Spectr, 2021 May 28
Lancet (London, England), 2013-03-09
The New England journal of medicine, 2018-07-12
Cancer, 2006-09-15
Cancer Discov,
Clin. Cancer Res.,
N. Engl. J. Med.,
The New England journal of medicine, 2016-07-21
The Lancet. Oncology, 2019-01
The Lancet. Oncology, 2017-12
J Thorac Oncol, 2016 Jul
Eur. J. Cancer, 2017 Aug 04
J Thorac Oncol, 2018 Feb
J. Clin. Oncol., 2018 Jun 15
The Lancet. Oncology, 2015-02
J. Clin. Oncol., 2017 Dec 14
NPJ breast cancer, 2017
The New England journal of medicine, 2018-06-14
N Engl J Med, 2018 Oct 20
The Lancet. Respiratory medicine, 2017-11
Ann. Thorac. Surg.,
Annals of surgical oncology, 2009-06
Annals of surgical oncology, 2017-02
Breast Cancer Res. Treat., 2017 Sep 15
JAMA, 2011-11-02
The New England journal of medicine, 2016-11-17
The Lancet. Oncology, 2016-04
Breast cancer research : BCR, 2016-06-28
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-01
Annals of surgical oncology, 2011-01
J Clin Oncol, 2011 Jan 10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-07-20
JAMA Oncol,
JAMA Oncol,
J. Clin. Oncol., 2020 Feb 20
J Clin Oncol, 2019 Jun 02
The New England journal of medicine, 2016-11-10
The New England journal of medicine, 2018-05-31
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-03-01
The Lancet. Oncology, 2013-10
Breast cancer research and treatment, 2017-06
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-04
The journals of gerontology. Series A, Biological sciences and medical sciences, 2001-03
Annals of oncology : official journal of the European Society for Medical Oncology, 2015-02
Medicine (Baltimore),
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-01
Arch Surg,
Lancet, 1998 Jul 25
Int. J. Radiat. Oncol. Biol. Phys., 2008-11-01
JAMA Oncol,
Lancet Oncol, 2021 Dec 15
N Engl J Med, 2011 Oct 6
Lancet Oncol., 2012-01-01
Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09
JAMA oncology, 2017-05-01
Clinical cancer research : an official journal of the American Association for Cancer Research, 2012-12-15
JAMA oncology, 2017-07-01
J. Clin. Oncol., 2017 Oct 02
The New England journal of medicine, 2015-02-19
Breast Cancer Res Treat, 2009 Jun
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019-02
JAMA, 2012 Jul 11
Radiation oncology (London, England), 2011-09-28
JAMA surgery, 2019-05-29
J. Clin. Oncol., 2020 Feb 27
Trials, 2013 Aug 19
Ann. Oncol., 2012 Jun 06
Cancer,
Clin Transl Oncol, 2018 Mar 28
N. Engl. J. Med., 2017 Jun 04
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-04-15
The New England journal of medicine, 2019-06-20
The New England journal of medicine, 2018-01-11
N. Engl. J. Med., 2019 May 31
The New England journal of medicine, 2018-12-06
J Thorac Oncol, 2019 Jan 18
The New England journal of medicine, 2019-02-14
N. Engl. J. Med.,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-01
The New England journal of medicine, 2012-02-09
Cancer control : journal of the Moffitt Cancer Center, 2009-01
JAMA, 2015-07-07
Clinical cancer research : an official journal of the American Association for Cancer Research, 2019-08-01
Nat Commun, 2019 Mar 27
Annals of surgery, 2019-04-05
The Lancet. Oncology, 2010-01
Breast Cancer Res. Treat.,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-06-15
J. Natl. Cancer Inst.,
PLoS ONE, 2018 May 16
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
International journal of radiation oncology, biology, physics, 2007-07-15
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-12-01
Lancet Oncol., 2015-03-01
Ann. Surg. Oncol., 2013 Nov 23
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01
Lancet Oncol., 2014-06-01
Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-02-01
Breast, 2013 Dec 22
Breast, 2015 Oct 09
Cancer,
J. Clin. Oncol., 2013 Aug 26
Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01
Cancer, 2005-04-15
Lung cancer (Amsterdam, Netherlands), 2015-12
Nature medicine, 2018-05
Cancer, 2017-11-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-20
Lancet (London, England), 2019-05-04
Annals of oncology : official journal of the European Society for Medical Oncology, 2015-07
European journal of cancer (Oxford, England : 1990), 2019-03
Lancet Oncol, 2019 May 20
Lung Cancer, 2012 Feb 10
N. Engl. J. Med., 2019 Sep 28
JAMA, 2014-05-21
Clin. Cancer Res., 2019 Aug 15
Ann. Oncol.,
Gastroenterology, 2018 May 17
Clin. Gastroenterol. Hepatol., 2018 Nov 28
Hepatology (Baltimore, Md.), 2019-10
Cancer, 2011-11-01
Case reports in oncology, 2017
BMC Cancer, 2015 Oct 15
JAMA oncology, 2019-06-01
Int J Cancer, 2018 Apr 15
JAMA Oncol, 2019 Oct 31
Eur J Surg Oncol, 2014 Oct 07
Breast cancer research and treatment, 2017-08
Ann. Oncol.,
The Lancet. Oncology, 2018-01
Annals of surgical oncology, 2018-08
Lancet Oncol., 2020 Feb 14
The Lancet. Oncology, 2010-10
Breast Cancer Res. Treat.,
Lancet, 2019 Oct 04
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-20
Cancer discovery, 2015-08
Annals of oncology : official journal of the European Society for Medical Oncology, 2018-10-01
Nature, 2014-07-31
Cancer discovery, 2015-08
J Clin Oncol, 2020 May 10
J Thorac Oncol, 2021 Oct 12
J. Clin. Oncol., 2019 Oct 16
Proceedings of the National Academy of Sciences of the United States of America, 2015-11-03
Oncologist, 2020 Mar 10
Semin Diagn Pathol, 2016 Dec 23
Lancet Oncol., 2015-09-01
Breast cancer research and treatment, 2014-11
The Lancet. Oncology, 2016-03
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-07-01
The New England journal of medicine, 2001-09-06
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-11-01
Lancet Oncol, 2020 Dec 07
Ann Oncol,
Lancet Oncol, 2021 Apr 13
J. Thorac. Cardiovasc. Surg.,
Cancer, 2015 Jan 06
Eur J Cardiothorac Surg,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-07-20
Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-12-01
JAMA Oncol, 2020 Aug 13
Journal of the National Cancer Institute, 2005-11-16
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10
N Engl J Med,
Lancet Oncol.,
British journal of cancer, 2011-06-07
N Engl J Med, 2021-04-01
Cancer, 2020 Jun 10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-10
Journal of the National Cancer Institute, 1997-11-19
Journal of surgical oncology, 2017-06
Annals of oncology : official journal of the European Society for Medical Oncology, 2000-08
Lancet Oncol., 2018 Nov 06
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-03-15
Clin Nutr, 2015 Aug 28
Obstet Gynecol,
JAMA,
Cancer Prev Res (Phila), 2019 Aug 16
The New England journal of medicine, 2017-01-12
Seminars in oncology, 2018-08
Endocrine-related cancer, 2016-09
Pancreas, 2017-07
JAMA Oncol, 2020 Apr 16
Pancreas, 2020 Jan
Surg Oncol Clin N Am, 2020 Oct 20
Scand J Gastroenterol, 2019 Aug 01
J Am Coll Surg, 2017 Jan 11
J Clin Oncol, 2018 Jun 07
Lancet Oncol., 2014-11-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10
N. Engl. J. Med., 2017-07-27
Ann. Oncol.,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-02-01
JAMA Oncol,
Urology, 2001-08
Br J Cancer,
The New England journal of medicine, 2016-03-03
Cancer immunology, immunotherapy : CII, 2017-01
Cancer, 2017-06-01
Journal of the American Academy of Dermatology, 2019-07-11
J Immunother,
Oncologist, 2020 Feb 11
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-09
J Thorac Dis,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-10
J Clin Oncol, 2019 Sep 18
Journal of clinical pharmacology, 2010-04
BJU Int, 2011 Oct
Anticancer Drugs,
Cancer, 2010-11-15
Ann Oncol, 2010 Feb 12
N Engl J Med, 2021 Mar 4
Cancer, 2000-03-15
Front Oncol, 2020 Dec 03
Annals of surgical oncology, 2018-07
Clinical genitourinary cancer, 2018-12
J Urol, 2020 Apr
Lancet, 2020 Mar 05
The New England journal of medicine, 2018-07-05
Lancet (London, England), 2018-03-24
J Gastroenterol, 2019 Nov 12
Am Heart J, 2010 Sep 18
N Engl J Med,
Lancet (London, England), 2017-01-07
The Lancet. Oncology, 2019-02
JAMA Oncol, 2020 Dec 10
Hepatology, 2019 Oct 14
Clin Imaging, 2021 Feb 10
N Engl J Med, 2020 May 14
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10
The New England journal of medicine, 2017-07-27
JAMA Oncol, 2021 Feb 18
Clinical breast cancer, 2008-06
Clinical genitourinary cancer, 2017-06
The Journal of urology, 2014-02
Journal of the National Comprehensive Cancer Network : JNCCN, 2018-01
Cancer medicine, 2019-01
Journal of the National Cancer Institute, 1988-07-06
Annals of oncology : official journal of the European Society for Medical Oncology, 2015-02
Anticancer Drugs,
J Adolesc Young Adult Oncol, 2019 Nov 08
N. Engl. J. Med., 2018-01-25
N. Engl. J. Med., 2019 Jun 02
N. Engl. J. Med., 2019 May 31
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-01
J. Clin. Oncol., 2019 Jul 22
Breast Cancer Res, 2020 Nov 04
Breast Cancer Res Treat, 2011 Jul 27
Clin Breast Cancer, 2019 May 24
J Clin Oncol, 2020 Sep 16
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-12-01
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-07-10
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-07-10
Oncologist, 2020 Dec 03
International journal of radiation oncology, biology, physics, 2018-10-01
Urology, 2000-11-01
Abdom Radiol (NY), 2019 Aug 29
Ann Oncol, 2007 Nov 15
Cancer Manag Res, 2012 Jun 13
Ann Oncol, 2007 Feb 13
J Clin Oncol, 2021 Feb 04
Biol Blood Marrow Transplant, 2019 Jul 01
Ann Hematol, 2015 Mar 27
Leuk Lymphoma, 2019 Nov 04
Ann Oncol, 2019 Oct 1
Int J Cancer, 2020 Dec 21
Adv Ther, 2020 Oct 29
Lancet, 2021 May 07
N. Engl. J. Med., 2016-10-13
Lancet, 2020 Sep 28
Lancet Oncol,
Lancet Oncol,
J Urol, 2020 Apr 13
Eur J Nucl Med Mol Imaging, 2020 Aug 12
J Urol,
Zhonghua Bing Li Xue Za Zhi,
Am J Transplant, 2016 Jun 09
Transplantation, 2021 Apr 27
Surgery, 2017 Jun 16
JAMA, 2011-02-09
Clinical genitourinary cancer, 2018-06
Cancer treatment and research communications, 2019
Urology, 2013-06
Prostate Cancer Prostatic Dis, 2020 Feb 28
Cancer, 2019 Dec 1
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-20
J Clin Oncol, 2021 Feb 02
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-01
Cancer, 2020 Mar 15
J Clin Oncol, 2021 Apr 06
Eur J Nucl Med Mol Imaging, 2018 Sep 28
Br J Radiol, 2018 Mar 20
Eur J Nucl Med Mol Imaging, 2013 Sep 13
BMC Cancer, 2019 Aug 08
Scand J Gastroenterol, 2021 Jan 20
Int J Endocrinol, 2021 Jan 23
Cancer Treat Rev, 2020 Dec 22
Clin Cancer Res,
Lancet Oncol, 2020 Jan
Eur J Cancer, 2020 Jun 27
European urology focus, 2018-12
Int J Radiat Oncol Biol Phys, 2015 Jul 15
Clin Genitourin Cancer, 2019 Mar 28
Int J Radiat Oncol Biol Phys, 2021 Feb 06
Lancet, 2021 Jan 21
Ann Oncol,
The New England journal of medicine, 2018-11-08
Eur J Haematol, 2021 Aug 11
Lancet Oncol, 2020 Oct 29
Blood Adv, 2021 Sep 01
Cell,
Am J Hematol, 2021 Jul 05
JAMA, 2016-11-15
N Engl J Med,
J Clin Oncol, 2019 Apr 10
J Clin Oncol, 2020 Feb 21
The Lancet. Oncology, 2019-01
J Clin Oncol, 2020 Oct 06
Lancet, 2019 Jun 03
Blood,
Mol Cell Endocrinol, 2021 Jan 26
Journal of clinical pathology, 2017-09
Leukemia, 2018-06
Int J Cancer, 2018 May 10
J. Clin. Oncol., 2020 Sep 20
Haematologica, 2021 Jun 01
J Urol, 2021 Feb 26
European urology, 2019-06
N Engl J Med, 2020 Sep 18
Cancer, 2020 Nov 20
Ann. Surg., 2019 Aug 30
Annals of surgical oncology, 2019-04
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10
The New England journal of medicine, 2015-11-05
Haematologica, 2018 May 24
Blood,
Leukemia, 2011 Jul 01
Haematologica, 2019 Sep 19
Blood, 2017 Aug 17
Blood, 2015 May 28
BJU international, 2011-09
Cancer, 2009-09-15
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-04-01
Clinical genitourinary cancer, 2016-02
Cancer, 2019-05-01
European urology, 2017-07
Int Urol Nephrol, 2007 Mar 02
Clin Genitourin Cancer, 2017 Jul 22
Clin Genitourin Cancer, 2020 Feb 08
Eur Urol, 2019 Nov 08
J Clin Oncol,
Clin Lymphoma Myeloma Leuk, 2020 Mar 07
Clin Lymphoma Myeloma Leuk, 2021 Jul 18
Blood Cancer J, 2021 Jan 11
N Engl J Med,
Blood cancer journal, 2018-06-12
J. Clin. Oncol., 2019 Oct 25
JAMA Oncol,
J Urol, 2020 Jul
Clin Cancer Res, 2020 Jan 22
Cancer, 2021 Apr 21
Eur Urol Oncol, 2019 Sep 19
N Engl J Med,
The New England journal of medicine, 2017-04-06
Invest New Drugs, 2017 Oct 25
Lancet Oncol, 2019 Oct 23
Blood, 2011-09-15
Haematologica, 2011 Dec 01
Cancer Chemother Pharmacol, 2016 Jun 10
Clin Cancer Res, 2020 Aug 17
N. Engl. J. Med., 2012-04-19
British journal of haematology, 2017-11
J Clin Oncol, 2016 Feb 29
Lancet Haematol, 2016 Dec 05
Lancet Oncol, 2022 Jan 21
N Engl J Med,
Annals of Oncology, 2021 Sep 29
Prostate cancer and prostatic diseases, 2018-04
JCO Precis Oncol, 2020
Lancet Oncol, 2019 Sep 09
Cancer, 2019 Jul 18
J Clin Oncol, 2021 Dec 10
The Lancet. Oncology, 2014-02
Front Oncol, 2018 Apr 17
Br J Cancer, 2021 Feb 03
Hepatogastroenterology, 2013 Jan 16
Medicine (Baltimore),
N. Engl. J. Med.,
Cancer Sci,
Oncotarget, 2017 May 10
Breast Cancer Res Treat, 2020 Sep 10
J Clin Oncol, 2022 Jan 18
J Clin Oncol, 2021 Aug 13
Lancet, 2016 Mar 19
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10
N Engl J Med, 2022 Feb 17
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-05-10
Lancet, 2019 Dec 12
Lancet (London, England), 2016-02-27
Blood, 2015-03-26
Blood,
Clin Lymphoma Myeloma Leuk, 2019 Oct 09
JCO Oncol Pract, 2019 Nov 25
Lancet Haematol,
Leukemia, 2020 Jul 21
World J Gastroenterol,
Lancet (London, England), 2019-01-19
Lancet Oncol, 2014 Oct 26
Blood cancer journal, 2016-07-29
Leukemia, 2022 Apr 11
The New England journal of medicine, 2018-08-23
Breast Cancer Res Treat, 2016 Feb 18
Mol Cancer Ther, 2018 Mar 28
Eur J Cancer, 2014 Aug 12
N Engl J Med, 2021 Jun 03
Am Soc Clin Oncol Educ Book,
Ann Oncol, 2013 Mar 01
N Engl J Med, 2020 Sep 19
Lancet, 2021 Sep 20
N Engl J Med, 2022 Apr 11
N Engl J Med, 2021 Dec 11
Lancet Oncol, 2020 Jun 05
J Clin Oncol, 2022 Jan 07
Oncotarget,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-10
Clinical genitourinary cancer, 2018-08